Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Public ClinicalTrials.gov record NCT02054130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Study identification
- NCT ID
- NCT02054130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 584 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2013
- Primary completion
- Dec 11, 2016
- Completion
- Feb 28, 2017
- Last update posted
- Dec 3, 2018
2013 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Miami | Florida | 33133 | — |
| Research Site | Oviedo | Florida | 32765 | — |
| Research Site | Savannah | Georgia | 31406 | — |
| Research Site | Peoria | Illinois | 61602 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Charlotte | North Carolina | 28277 | — |
| Research Site | Dublin | Ohio | 43016 | — |
| Research Site | Oklahoma City | Oklahoma | 73120 | — |
| Research Site | Rock Hill | South Carolina | 29732 | — |
| Research Site | Spartanburg | South Carolina | 29303 | — |
| Research Site | Houston | Texas | 77070 | — |
| Research Site | Richmond | Virginia | 23220 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02054130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2018 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02054130 live on ClinicalTrials.gov.